Oncolytics Biotech disengages Ernst & Young, engages Baker Tilly as auditor
Oncolytics Biotech Inc. disengaged Ernst & Young LLP as its independent registered public accounting firm and engaged Baker Tilly US, LLP as its auditor for the 2026 fiscal year, effective July 6, 2026, due to the Company's corporate restructuring. EY's prior audit reports for fiscal years ended December 31, 2025 and 2024 contained no adverse opinions or disclaimers, though they included explanatory paragraphs regarding the Company's ability to continue as a going concern. There were no disagreements with EY on accounting principles, disclosure, or auditing procedures.
Key facts
- Ernst & Young LLP disengaged July 6, 2026
- Baker Tilly US, LLP engaged for 2026 fiscal year
- Change due to Company's corporate restructuring
- EY's reports on fiscal years ended December 31, 2025 and December 31, 2024 contained explanatory paragraph regarding going concern
- No disagreements with EY on accounting principles, disclosure, or audit scope through date of change
- No reportable events within meaning of Item 304(a)(1)(v) of Regulation S-K during fiscal years 2025 and 2024
Why it matters
The auditor change coincides with the Company's stated corporate restructuring and occurs under a going-concern audit qualification, signaling material changes to the Company's financial condition or operational structure that prompted both internal accounting firm transition and prior audit concerns about continuity.
Share
Derived from 8-K filed 2026-07-08. Not investment advice. View the source filing on SEC.gov →